American Molecular Laboratories’ Post

Part Two: One of Professor Turner’s works is focused on phage therapy and its potential to restore antibiotic sensitivity in multi-drug resistant Pseudomonase aeruginosa. The title of work is ‘‘Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa’’ https://lnkd.in/d9zCmVR6

Check out our protocol for lipid mediator profiling of human macrophages during host-pathogen interaction, which we just published in STAR protocols. Here, we show several pathogen incubation techniques, such as Staphylococcus aureus but also Influenza A virus, which we established in the last years. @ Kerstin Günther well done! #lipidmediators #pathogens

The global rise of antimicrobial resistance has led to a renewed interest in phage therapy for treating bacterial infections. Isolating suitable phages for research is crucial, especially for combating Acinetobacter baumannii, known for its antibiotic resistance. A new lytic phage, Mystique, was discovered and characterized, showing a broad host range against A. baumannii strains. The study highlights how environmental conditions can significantly affect phage infectivity, impacting isolation and characterization efforts. https://buff.ly/4bQRJGM

K. pneumoniae is one of the most dangerous pathogens in our society, as determined by the World Health Organization. It can display high degrees of virulence and antibiotic💊🔬 resistance, making it extremely difficult to treat. This pathogen also forms biofilms, which are responsible for most infections in humans. Excited to share this wonderful collaboration led by the great Renee Fleeman that shows new ways to collapse biofilms caused by this bacterial pathogen 🧫🔬 published in Cell Reports Physical Science Cell Press. Thrilled to see the development of out-of-the-box approaches and countermeasures to target biofilms caused by this priority pathogen! https://lnkd.in/eMJ26D4U

AMR - Antiomocrbial Resistant Bacrterias are pervasive across every area of the health care system What were once simple surgical procedures will soon be riddled with life altering complications Life saving cancer therapies will rid the human body of cancer, but success will be thwarted by the once “simple” and easily treatable infections I see the pursuit of new classes of antibiotics treatment not only as a responsibility, but as a critical enabler of life saving therapies across ALL areas of medicine [Announcments coming soon]

One of our investigators, Dr Jeantelle Du Preez, recently presented promising findings at the CROI Conference in Denver, Colorado. Our study focuses on the innovative combination of Alpibectir and Ethionamide (AlpE), which offers a new approach to tuberculosis treatment. Alpibectir is designed to enhance the activity of Ethionamide by stimulating an alternative pathway for bacterial bioactivation. This allows for lower drug doses while retaining strong bactericidal activity, potentially reducing common side effects associated with higher doses of Ethionamide. Key findings from the first stage of the trial indicate that the AlpE combination is not only well-tolerated but also shows bactericidal activity comparable to standard isoniazid, with fewer side effects. With the study now fully enrolled, we are excited about the impact this could have on both drug-susceptible and resistant forms of TB. We look forward to further developments as we analyse the results and seek to optimize this promising treatment. #TBInnovation #AlpECombo #CROIFindings #ClinicalResearch

[Life Sciences] Discover our new LEAP-2 Elisa kit! 👨🔬   As a member of the antimicrobial peptide family, LEAP-2, or Liver-Expressed Antimicrobial Peptide 2, plays a crucial role in the body's innate immune system, serving as a natural defense mechanism against a variety of microbial threats. Besides that, it is also involved in metabolic mechanisms as it is an antagonist of Ghreline. Understanding the function and regulation of LEAP-2 has implications for the development of new therapeutic strategies for infectious diseases, inflammatory conditions, and gastrointestinal disorders. In this new Application Note, discover the good performance of the new LEAP2 ELISA kit developed by Bertin Technologies.   https://lnkd.in/d2cHn7HD Nabil Zerrari

New paper published (open access) in the Heliyon journal (https://lnkd.in/dJrGBcc2), thanks to a very nice collaboration between researchers from the Universidad de Zaragoza (Spain), the University of Lübeck (Germany) and the German Center for Infection Research (Germany). In this work we unveiled for the first time the direct antimicrobial effect of the hormone L-thyroxine (T4) and a set of derivatives on bacteria of the genus Streptococcus. By relying on in-vitro experiments and in silico approaches we have tested the activity and toxicity of these compounds and described the structural determinants influencing their antibacterial efficacy. Interestingly, some of the analogues showing promising therapeutic profiles against Streptococcus pneumoniae and other Gram-positive bacteria are known to have a greatly reduced hormonal effect, compared to thyroxine, which is good and allow for a further development of narrow spectrum antimicrobials. #DrugDiscovery #DrugDesign #Streptococcus #Grampositivebacteria #Narrowspectrumantimicrobials #MolecularDocking

QIAstat-Dx Analyzer - QIAGEN Meningitis Panel Done ✔️ 1- CSF sample + H.Influenza 2- CSF sample + HHV6

I'm very excited to share that our review on phosphoethanolamine-modified LPS and phosphoethanolamine transferases has been published! LPS are essential to many Gram-negative bacteria and modifications to LPS have a long standing role in bacterial virulence and the stress response. In this review we specifically examined how phosphoethanolamine modifications to LPS/lipid A are regulated, impact virulence, fitness, and resistance to AMPs and polymyxins. We also looked into mobile colistin resistance (mcr) genes which are mobile phosphoethanolamine transferases of high interest due to their ability to confer resistance to last resort antibiotic colistin. Read more here: